apomorphine has been researched along with Cognition Disorders in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ares, B; Castro, A; Fernández-Pajarín, G; Rivas, MT; Sesar, Á | 1 |
| Brosda, J; Fink, H; Franke, RT; Pertz, HH; Tarland, E | 1 |
| Nagy, H; Radics, P; Takáts, A; Tamás, G; Tóth, A | 1 |
| Chen, J; Chen, S; Lei, W; Li, Y; Luo, C; Ma, Y; OuYang, L; Wu, J; Zhan, M | 1 |
| Domanska-Janik, K; Drela, K; Gornicka-Pawlak, EB; Habich, A; Jablonska, A; Janowski, M; Kozlowska, H; Lukomska, B; Sypecka, J | 1 |
| Kulisevsky, J; Martí, MJ | 1 |
| Antonini, A; Basile, G; Di Blasi, L; Di Raimondo, G; Di Rosa, AE; Epifanio, A; Imbesi, D; La Spina, P; Martino, G; Morgante, L; Stocchi, F; Tetto, A | 1 |
| Antonini, A; Basile, G; Di Rosa, AE; Di Rosa, E; Epifanio, A; La Spina, P; Marconi, R; Martino, G; Morgante, L; Nicita-Mauro, V; Spina, E; Stocchi, F | 1 |
| Alegret, M; Junqué, C; Martí, M; Pilleri, M; Rumià, J; Tolosa, E; Valldeoriola, F | 1 |
| Eberle, EL; Jones, CK; McKinzie, DL; Shannon, HE; Shaw, DB | 1 |
| Antonini, A; Bonetti, A; Cilia, R; De Gaspari, D; Landi, A; Mariani, CB; Morgante, L; Natuzzi, F; Pezzoli, G; Sganzerla, E; Siri, C | 1 |
| Gilles, C; Luthringer, R | 1 |
| Jech, R; Mecír, P; Roth, J; Růzicka, E; Spacková, N | 1 |
| Becker, A; Bernstein, HG; Bogerts, B; Grecksch, G; Höllt, V | 1 |
| Austin, MP; Chan, J; Eyers, K; Hadzi-Pavlovic, D; Hickie, I; Mitchell, P; Parker, G | 1 |
| Carnoy, P; Ravard, S; Simon, P; Soubrie, P; Wemerman, B | 1 |
3 review(s) available for apomorphine and Cognition Disorders
| Article | Year |
|---|---|
[Treatment possibilities in advanced Parkinson's disease].
Topics: Administration, Oral; Age Factors; Antiparkinson Agents; Apomorphine; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Dopamine Agents; Drug Tolerance; Duodenum; Dyskinesia, Drug-Induced; Gels; Humans; Infusion Pumps, Implantable; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2013 |
[Candidate patient for treatment with continuous apomorphine infusion].
Topics: Aged; Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Cognition Disorders; Contraindications; Depression; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Hallucinations; Humans; Infusions, Intravenous; Middle Aged; Parkinson Disease; Patient Selection; Psychoses, Substance-Induced; Psychotic Disorders | 2012 |
Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs.
Topics: Apomorphine; Cognition Disorders; Dopamine Agonists; Excitatory Amino Acid Antagonists; GABA Modulators; Humans; Ketamine; Lorazepam; Memory Disorders; Models, Psychological; Muscarinic Antagonists; Panic Disorder; Psychotropic Drugs; Scopolamine; Tryptophan | 2007 |
3 trial(s) available for apomorphine and Cognition Disorders
| Article | Year |
|---|---|
Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
Topics: Antiemetics; Apomorphine; Brain; Cognition Disorders; Depression; Domperidone; Dopamine Agonists; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires | 2004 |
Apomorphine induced cognitive changes in Parkinson's disease.
Topics: Apomorphine; Cognition Disorders; Evoked Potentials, Auditory; Evoked Potentials, Visual; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time | 1994 |
Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report.
Topics: Aged; Apomorphine; Cognition Disorders; Cross-Over Studies; Depressive Disorder, Major; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Disorders; Severity of Illness Index | 2000 |
10 other study(ies) available for apomorphine and Cognition Disorders
| Article | Year |
|---|---|
Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Cognition Disorders; Cohort Studies; Dopamine Agonists; Dyskinesias; Female; Humans; Infusions, Subcutaneous; Male; Middle Aged; Parkinson Disease; Sensation Disorders; Severity of Illness Index; Treatment Outcome | 2017 |
Effects of 2-bromoterguride, a dopamine D
Topics: Animals; Antipsychotic Agents; Apomorphine; Cognition Disorders; Dopamine Agonists; Lisuride; Male; Memory Disorders; Phencyclidine; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Recognition, Psychology; Reflex, Startle; Schizophrenic Psychology; Social Behavior | 2018 |
The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Choline O-Acetyltransferase; Cognition Disorders; Corpus Striatum; Creatine; Interneurons; Male; Maze Learning; Medial Forebrain Bundle; Movement Disorders; Muscle Strength; Neuropeptide Y; Oxidopamine; Parvalbumins; Rats; Rats, Sprague-Dawley; Spatial Behavior; Tyrosine 3-Monooxygenase | 2014 |
Systemic treatment of focal brain injury in the rat by human umbilical cord blood cells being at different level of neural commitment.
Topics: Analysis of Variance; Animals; Antigens, CD34; Apomorphine; Brain Injuries; Cognition Disorders; Disease Models, Animal; Exploratory Behavior; Fetal Blood; Gene Expression Regulation; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intra-Arterial; Locomotion; Male; Movement Disorders; Nerve Tissue Proteins; Neurons; Neuropsychological Tests; Psychomotor Performance; Rats; Rats, Wistar; Recognition, Psychology; Rotation; Time Factors; Vibrissae | 2011 |
Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
Topics: Aged; Apomorphine; Cognition Disorders; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Humans; Levodopa; Longitudinal Studies; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales | 2003 |
Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease.
Topics: Aged; Apomorphine; Cognition Disorders; Deep Brain Stimulation; Dopamine Agonists; Electrodes, Implanted; Female; Functional Laterality; Humans; Injections, Subcutaneous; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Time Factors | 2004 |
Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats.
Topics: Acoustic Stimulation; Animals; Apomorphine; Benzazepines; Cognition Disorders; Dose-Response Relationship, Drug; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Muscarinic; Reflex; Reflex, Startle | 2005 |
Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cognition Disorders; Deep Brain Stimulation; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus | 2006 |
Disruption of latent inhibition in rats with postnatal hippocampal lesions.
Topics: Anesthesia; Animals; Apomorphine; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agonists; Hippocampus; Ibotenic Acid; Learning; Motor Activity; Neural Inhibition; Rats; Rats, Sprague-Dawley; Schizophrenic Psychology | 1999 |
Behavioral deficits induced by low doses of apomorphine in rats: evidence for a motivational and cognitive dysfunction which discriminates among neuroleptic drugs.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Cognition Disorders; Conditioning, Operant; Dopamine; Male; Motivation; Motor Activity; Rats; Rats, Inbred Strains; Reinforcement, Psychology; Synaptic Transmission | 1986 |